The company hopes that its patented biochemical sensor featuring optical microchips will pave the way in increasing its market share.
The SpectroSens device is able to detect all classes of biological targets, including proteins, toxins, viruses and bacteria, as well as measuring changes in the chemical composition of liquids.
The market for chemical sensors is forecast to grow considerably in the next few years. Stratophase believes that its technical developments in enabling miniaturisation and increasing cost efficiency will allow it to make the most of these opportunities.
Over the past year Stratophase has increased its in-house capabilities, upgraded its bio-assay development facility and advanced its integrated optical chip development and production activities. In addition, it has increased its workforce to support the development of its SpectroSens device.
This expansion builds on significant contract wins last year, which included a high-profile contract with the UK Ministry of Defence, as well as deals with the Technology Strategy Board and the Home Office.
Richard Williams, chief executive of Stratophase, said: ‘Our business strategy includes various market sectors, including life sciences, pharmaceutical manufacturing, food and drink manufacturing, and point-of-care diagnostics, and is based on the SpectroSens chip technology’s wide range of applications.
‘The recent funding will enable us to further develop, demonstrate and commercialise SpectroSens systems through collaboration, partnering and licensing activities with established market players. We are also developing and adapting the core SpectroSens technology for specific customer requirements.’